default author photo

Dengfeng Cao

Shanghai Jiao Tong University (SJTU)

SCHOLARLY PAPERS

1

DOWNLOADS

48

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Tislelizumab Plus Lenvatinib as the First-Line Therapy in Patients with Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Single-Arm, Single-Centre, Phase 2 Trial and Metabolic Biomarker Analysis

Number of pages: 33 Posted: 07 Oct 2025
Wen Kong, Yunze Xu, Guiqin Liu, Zaoyu Wang, Dengfeng Cao, Wenwen Lv, Feng Jiao, Jiong Hu, Xiaoyu Wu, Jiwei Huang, Yonghui Chen, Wei Zhai, Xiaorong Wu, Jiahua Pan, Yiran Huang, Guangyu Wu, Liang Zheng, Wei Xue and Jin Zhang
Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU) - Department of Urology, Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU) - Department of Urology, Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU) - Department of Radiology, Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU) and Shanghai Jiao Tong University (SJTU)
Downloads 48 (1,109,210)

Abstract:

Loading...

Fumarate hydratase-deficient renal cell carcinoma, immune checkpoint inhibitor, tyrosine kinase inhibitor, succinate-modifying metabolites